136 related articles for article (PubMed ID: 27444341)
21. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
Olsson A; Norberg M; Okvist A; Derkow K; Choudhury A; Tobin G; Celsing F; Osterborg A; Rosenquist R; Jondal M; Osorio LM
Br J Cancer; 2007 Sep; 97(6):769-77. PubMed ID: 17726463
[TBL] [Abstract][Full Text] [Related]
22. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
23. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
24. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Willimott S; Baou M; Naresh K; Wagner SD
Br J Haematol; 2007 Sep; 138(6):721-32. PubMed ID: 17760804
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
26. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
27. Targeting Bcl-2 in CLL.
Rogalinska M; Kilianska ZM
Curr Med Chem; 2012; 19(30):5109-15. PubMed ID: 22856663
[TBL] [Abstract][Full Text] [Related]
28. Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA; Huang D; Roberts A
Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
[TBL] [Abstract][Full Text] [Related]
29. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
[TBL] [Abstract][Full Text] [Related]
30. Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics.
Harris MM; Coon Z; Alqaeisoom N; Swords B; Holub JM
Org Biomol Chem; 2016 Jan; 14(2):440-446. PubMed ID: 26563651
[TBL] [Abstract][Full Text] [Related]
31. Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.
Stroffekova K; Tomkova S; Huntosova V; Kozar T
Photodiagnosis Photodyn Ther; 2019 Dec; 28():38-52. PubMed ID: 31430575
[TBL] [Abstract][Full Text] [Related]
32. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
33. Functional Implications of the spectrum of BCL2 mutations in Lymphoma.
Singh K; Briggs JM
Mutat Res Rev Mutat Res; 2016; 769():1-18. PubMed ID: 27543313
[TBL] [Abstract][Full Text] [Related]
34. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
35. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis.
Mai H; May WS; Gao F; Jin Z; Deng X
J Biol Chem; 2003 Jan; 278(3):1886-91. PubMed ID: 12421819
[TBL] [Abstract][Full Text] [Related]
36. Cloning of the bovine antiapoptotic regulator, BCL2-related protein A1, and its expression in trophoblastic binucleate cells of bovine placenta.
Ushizawa K; Takahashi T; Kaneyama K; Hosoe M; Hashizume K
Biol Reprod; 2006 Feb; 74(2):344-51. PubMed ID: 16221993
[TBL] [Abstract][Full Text] [Related]
37. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
39. Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL.
Mc Gee MM; Greene LM; Ledwidge S; Campiani G; Nacci V; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2004 Sep; 310(3):1084-95. PubMed ID: 15143129
[TBL] [Abstract][Full Text] [Related]
40. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
